Pharmaceuticals

Global Genomic Biomarker Market Forecast 2026–2035: Long-Term Growth Insights

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the genomic biomarker market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Genomic Biomarker Market covering 2026–2035?

The genomic biomarker market size has seen rapid expansion in recent years. It is anticipated to grow from $9.9 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.8%. The observed growth during the past period can be ascribed to a rise in investment in genomic research, an increase in oncology-focused biomarker studies, the growing availability of next-generation sequencing technologies, enhanced collaboration between diagnostics and pharma companies, and the initial adoption of personalized medicine approaches.

The genomic biomarker market is projected for substantial expansion in the coming years, with its size expected to reach $22.23 billion by 2030, reflecting a compound annual growth rate (CAGR) of 17.5%. This growth in the forecast period is attributable to an increasing demand for precision medicine therapies, the rising use of biomarkers in drug development, the expansion of companion diagnostics adoption, a growing focus on early disease detection, and increasing regulatory support for biomarker-based approvals. Major trends anticipated during this period include the increasing adoption of predictive genomic biomarkers, the rising use of pharmacogenomic testing, growing integration of genomic data in clinical decision-making, the expansion of biomarker-based oncology diagnostics, and an enhanced focus on clinical validation standards.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Genomic Biomarker Market?

The growing occurrence of chronic illnesses is anticipated to boost the expansion of the genomic biomarker market in the future. These are enduring health conditions that persist over extended periods and typically advance gradually. The rising incidence of chronic ailments stems from an aging global population and an uptick in lifestyle-associated conditions like obesity and diabetes. Genomic biomarkers facilitate early identification and customized prevention methods for chronic diseases by pinpointing genetic vulnerabilities and customizing treatments. Such a proactive strategy aids in reducing their widespread occurrence by focusing on individuals at risk prior to the onset of the disease. For example, data from September 2023, provided by the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicates that 41 million deaths occur globally each year, representing 74% of all mortalities due to chronic conditions. This figure comprises 17.9 million deaths attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2.0 million to diabetes. Consequently, the escalating presence of chronic diseases acts as a catalyst for the expansion of genomic biomarkers.

What Leading Segments Are Studied In The Genomic Biomarker Market?

The genomic biomarker market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users

Subsegments:

1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction

2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

Which Trends Are Expected To Influence The Genomic Biomarker Market In The Upcoming Years?

Leading firms within the genomic biomarker market are concentrating on creating sophisticated products, such as advanced liquid biopsy assays, to facilitate thorough genomic profiling of solid tumors. A liquid biopsy assay serves as a diagnostic tool, examining genetic material, predominantly circulating tumor DNA (ctDNA), obtained from a blood sample for the purpose of identifying and tracking cancer. Pinpointing genomic biomarkers offers insights into particular mutations, gene expression patterns, or other genetic changes linked to cancer. An example of this is that in November 2023, Illumina Inc., a US-based biotechnology company, introduced an advanced liquid biopsy assay, specifically the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), which is designed for comprehensive genomic profiling of solid tumors. This assay provides improved analytical sensitivity, capable of detecting low-frequency variants using merely 20 ng of cell-free DNA, a reduction from the previous 30 ng requirement. Results are provided in under four days, considerably speeding up genomic profiling in contrast to conventional approaches. Its optimized workflow and upcoming automation features are set to simplify laboratory integration and enhance overall efficiency.

Which Major Industry Participants Are Leading The Genomic Biomarker Market Growth?

Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Genomic Biomarker Market?

North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Genomic Biomarker Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20557&type=smp

Browse Through More Reports Similar to the Global Genomic Biomarker Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795